AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (686.7 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations

Zongchao Mo1,2,*Junyi Xin1,*Ruichao Chai1,3Peter Y.M. Woo4,5Danny T.M. Chan6Jiguang Wang1,2,7,8( )
Division of Life Science and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China
HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Shenzhen 518000, China
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
Department of Neurosurgery, Kwong Wah Hospital, Hong Kong SAR, China
Hong Kong Neuro-Oncology Society, Hong Kong SAR, China
Division of Neurosurgery, Department of Surgery, Prince of Wales Hospital, Hong Kong SAR, China
Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Understanding the racial specificities of diseases—such as adult diffuse glioma, the most common primary malignant tumor of the central nervous system—is a critical step toward precision medicine. Here, we comprehensively review studies of gliomas in East Asian populations and other ancestry groups to clarify the racial differences in terms of epidemiology and genomic characteristics. Overall, we observed a lower glioma incidence in East Asians than in Whites; notably, patients with glioblastoma had significantly younger ages of onset and longer overall survival than the Whites. Multiple genome-wide association studies of various cohorts have revealed single nucleotide polymorphisms associated with overall and subtype-specific glioma susceptibility. Notably, only 3 risk loci—5p15.33, 11q23.3, and 20q13.33—were shared between patients with East Asian and White ancestry, whereas other loci predominated only in particular populations. For instance, risk loci 12p11.23, 15q15-21.1, and 19p13.12 were reported in East Asians, whereas risk loci 8q24.21, 1p31.3, and 1q32.1 were reported in studies in White patients. Although the somatic mutational profiles of gliomas between East Asians and non-East Asians were broadly consistent, a lower incidence of EGFR amplification in glioblastoma and a higher incidence of 1p19q-IDH-TERT triple-negative low-grade glioma were observed in East Asian cohorts. By summarizing large-scale disease surveillance, germline, and somatic genomic studies, this review reveals the unique characteristics of adult diffuse glioma among East Asians, to guide clinical management and policy design focused on patients with East Asian ancestry.

Electronic Supplementary Material

Download File(s)
cbm-19-10-1440_ESM1.xlsx (25.7 KB)
cbm-19-10-1440_ESM2.docx (31.7 KB)

References

1

Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23: Ⅲ1-105.

2

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.

3

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803-20.

4

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23: 1231-51.

5
Cote DJ, Ostrom QT. Epidemiology and etiology of glioblastoma BT - precision molecular pathology of glioblastoma. In: Otero JJ, Becker AP, editors. Cham: Springer International Publishing; 2021. p. 3-19.
6

Braganza MZ, Kitahara CM, de González AB, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012; 14: 1316-24.

7

Lan YL, Zhu Y, Chen G, Zhang J. The promoting effect of traumatic brain injury on the incidence and progression of glioma: a review of clinical and experimental research. J Inflamm Res. 2021; 14: 3707-20.

8

Ostrom QT, Edelson J, Byun J, Han Y, Kinnersley B, Melin B, et al. Partitioned glioma heritability shows subtype-specific enrichment in immune cells. Neuro Oncol. 2021; 23: 1304-14.

9

Rice T, Lachance DH, Molinaro AM, Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, et al. Understanding inherited genetic risk of adult glioma - a review. Neurooncol Pr. 2016; 3: 10-6.

10

Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019; 47: D1005-12.

11

Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet. 2012; 90: 7-24.

12

Kinnersley B, Houlston RS, Bondy ML. Genome-wide association studies in Glioma. Cancer Epidemiol Biomarkers Prev. 2018; 27: 418-28.

13

Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155: 462-77.

14

McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-8.

15

Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-12.

16

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018; 4: 1254-62.

17

Maile EJ, Barnes I, Finlayson AE, Sayeed S, Ali R. Nervous system and intracranial tumour incidence by ethnicity in England, 2001-2007: a descriptive epidemiological study. PLoS One. 2016; 11: 2001-7.

18

Kang H, Song SW, Ha J, Won YJ, Park CK, Yoo H, et al. A nationwide, population-based epidemiology study of primary central nervous system tumors in Korea, 2007-2016: a comparison with United States Data. Cancer Res Treat. 2021; 53: 355-66.

19

Chien LN, Gittleman H, Ostrom QT, Hung KS, Sloan AE, Hsieh YC, et al. Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry. Front Public Heal. 2016; 4: 1-8.

20

Narita Y, Shibui S. Trends and outcomes in the treatment of gliomas based on data during 2001–2004 from the brain tumor registry of Japan. Neurol Med Chir (Tokyo). 2015; 55: 286-95.

21

Koo H, Choi SW, Cho HJ, Lee IH, Kong DS, Seol HJ, et al. Ethnic delineation of primary glioblastoma genome. Cancer Med. 2020; 9: 7352-9.

22

Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade Ⅱ and Ⅲ gliomas. Nat Genet. 2015; 47: 458-68.

23

Chan AK, Mao Y, Ng HK. TP53 and Histone H3.3 mutations in triple-negative lower-grade gliomas. N Engl J Med. 2016; 375: 2206-8.

24

Zeng C, Wang J, Li M, Wang H, Lou F, Cao S, et al. Comprehensive molecular characterization of chinese patients with glioma by extensive next-generation sequencing panel analysis. Cancer Manag Res. 2021; 13: 3573-88.

25

Low JT, Ostrom QT, Cioffi G, Neff C, Waite KA, Kruchko C, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): a summary of the CBTRUS statistical report for clinicians. Neurooncology Pract. 2022; 9: 165-82.

26

Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21: V1-100.

27

Lin D, Wang M, Chen Y, Gong J, Chen L, Shi X, et al. Trends in intracranial glioma incidence and mortality in the United States, 1975-2018. Front Oncol. 2021; 11: 748061.

28

Chang L, Su J, Jia X, Ren H. Treating malignant glioma in Chinese patients: update on temozolomide. Onco Targets Ther. 2014; 7: 235-44.

29

Nakamura H, Makino K, Yano S, Kuratsu JI. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan-20-year study. Int J Clin Oncol. 2011; 16: 314-21.

30

Matsumoto F, Takeshima H, Yamashita S, Yokogami K, Watanabe T, Ohta H. Epidemiologic study of primary brain tumors in Miyazaki prefecture: a regional 10-year survey in southern Japan. Neurol Med Chir (Tokyo). 2021; 61: 492-8.

31

Dho YS, Jung KW, Ha J, Seo Y, Park CK, Won YJ, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017; 5: 16.

32

Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015; 51: 533-42.

33

Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009; 95: 401-11.

34

Gramatzki D, Dehler S, Rushing EJ, Zaugg K, Hofer S, Yonekawa Y, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer. 2016; 122: 2206-15.

35

Korja M, Raj R, Seppä K, Luostarinen T, Malila N, Seppälä M, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol. 2019; 21: 370-9.

36

Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, et al. Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2019; 142: 91-101.

37

Ho VKY, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014; 50: 2309-18.

38

He Z, Wong ST, Yam KY. Newly-diagnosed, histologically-confirmed central nervous system tumours in a regional hospital in hong kong: an epidemiological study of a 21-year period. J Korean Neurosurg Soc. 2019; 63: 119-35.

39
Woo PYM, Yau S, Lam TC, Pu JKS, Li LF, Lui LCY, et al. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period. Neurooncology Pract. Published online first: Sep 10, 2022. DOI: 10.1093/nop/npac069.
40

Pu JKS, Ng GKB, Leung GKK, Wong CK. One-year review of the incidence of brain tumours in Hong Kong Chinese patients as part of the Hong Kong Brain and Spinal Tumours Registry. Surg Pract. 2012; 16: 133-6.

41

Lee CH, Jung KW, Yoo H, Park S, Lee SH. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010; 48: 145-52.

42

Jung KW, Ha J, Lee SH, Won YJ, Yoo H. An updated nationwide epidemiology of primary brain tumors in republic of Korea. Brain tumor Res Treat. 2013; 1: 16-23.

43

Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012; 48: 1532-42.

44

Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro Oncol. 2017; 19: 1553-64.

45

Hansen S, Rasmussen BK, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM, et al. Treatment and survival of glioblastoma patients in Denmark: the Danish Neuro-Oncology Registry 2009–2014. J Neurooncol. 2018; 139: 479-89.

46

Jung KW, Yoo H, Kong HJ, Won YJ, Park S, Lee SH. Population-based survival data for brain tumors in Korea. J Neurooncol. 2012; 109: 301-7.

47

Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013; 113: 259-66.

48

Hodges TR, Labak CM, Mahajan UV, Wright CH, Wright J, Cioffi G, et al. Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. Neurooncology Adv. 2021; 3: 1-12.

49

Wang P, Liu Y, Zhi L, Qiu X. Integrated analysis of the clinical and molecular characteristics of IDH wild-type gliomas in the Chinese glioma genome atlas. Front Oncol. 2021; 11: 1-9.

50

Lin Z, Yang R, Li K, Yi G, Li Z, Guo J, et al. Establishment of age group classification for risk stratification in glioma patients. BMC Neurol. 2020; 20: 1-11.

51

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017; 133: 1001-16.

52

Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS. Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer. 2014; 120: 238-43.

53

Bohn A, Braley A, de la Vega PR, Carlos Zevallos J, Barengo NC. The association between race and survival in glioblastoma patients in the US: a retrospective cohort study. PLoS One. 2018; 13: 1-10.

54

Xu H, Chen J, Xu H, Qin Z. Geographic variations in the incidence of glioblastoma and prognostic factors predictive of overall survival in US adults from 2004-2013. Front Aging Neurosci. 2017; 9: 1-9.

55

Haque W, Verma V, Butler EB, Teh BS. Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma. J Neurooncol. 2017; 135: 173-81.

56

Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci. 2018; 47: 103-10.

57

Thumma SR, Fairbanks RK, Lamoreaux WT, Mackay AR, Demakas JJ, Cooke BS, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012; 10: 1-12.

58
Bakirarar B, Egemen E, Yakar F. Machine learning model to identify prognostic factors in glioblastoma: a SEER-Based analysis. Published online first: Feb, 2022. DOI: 10.21203/rs.3.rs-1327181/v1.
59

Gittleman H, Boscia A, Ostrom QT, Truitt G, Fritz Y, Kruchko C, et al. Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. Neuro Oncol. 2018; 20: Ⅶ6-16.

60

Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. Eur J Cancer. 2015; 51: 2231-41.

61

Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y, et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet. 2011; 20: 2897-904.

62

Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41: 899-904.

63

Li N, Shi H, Hou P, Gao L, Shi Y, Mi W, et al. Genetic variants of CYP4F12 gene are associated with glioma susceptibility. Int J Cancer. 2021; 149: 1910-5.

64

Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011; 43: 1098-103.

65

Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet. 2012; 44: 1122-5.

66

Chen H, Chen G, Li G, Zhang S, Chen H, Chen Y, et al. Two novel genetic variants in the STK38L and RAB27A genes are associated with glioma susceptibility. Int J Cancer. 2019; 145: 2372-82.

67

Liu Y, Zhou Y, Zhu K. Inhibition of glioma cell lysosome exocytosis inhibits glioma invasion. PLoS One. 2012; 7: e45910.

68

Wu X, Hu A, Zhang M, Chen Z. Effects of Rab27a on proliferation, invasion, and anti-apoptosis in human glioma cell. Tumour Biol. 2013; 34: 2195-203.

69

Stark K, Schauer L, Sahlen GE, Ronquist G, Oliw EH. Expression of CYP4F12 in gastrointestinal and urogenital epithelia. Basic Clin Pharmacol Toxicol. 2004; 94: 177-83.

70

Tian Y, Yang T, Yu S, Liu C, He M, Hu C. Prostaglandin E2 increases migration and proliferation of human glioblastoma cells by activating transient receptor potential melastatin 7 channels. J Cell Mol Med. 2018; 22: 6327-37.

71

Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014; 46: 731-5.

72

Kinnersley B, Labussière M, Holroyd A, Di Stefano AL, Broderick P, Vijayakrishnan J, et al. Genome-wide association study identifies multiple susceptibility loci for glioma. Nat Commun. 2015; 6: 1-9.

73

Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017; 49: 789-94.

74

Eckel-Passow JE, Decker PA, Kosel ML, Kollmeyer TM, Molinaro AM, Rice T, et al. Using germline variants to estimate glioma and subtype risks. Neuro Oncol. 2019; 21: 451-61.

75

Eckel-Passow JE, Drucker KL, Kollmeyer TM, Kosel ML, Decker PA, Molinaro AM, et al. Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C. Neuro Oncol. 2020; 22: 1602-13.

76

Eckel-Passow JE, Lachance DH, Decker PA, Kollmeyer TM, Kosel ML, Drucker KL, et al. Inherited genetics of adult diffuse glioma and polygenic risk scores—a review. Neurooncology Pract. 2022; 9: 259-270.

77

Choi J, Jia G, Wen W, Long J, Zheng W. Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants. Int J Cancer. 2020; 147: 3416-23.

78

Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018; 175: 1665-78.e18.

79

Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DIS, Zairis S, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016; 48: 768-76.

80

Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017; 49: 594-9.

81

Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteomics Bioinformatics. 2021; 19: 1-12.

82

Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed latin American populations. Cancer Discov. 2021; 11: 591-8.

83

Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, et al. Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res. 2001; 61: 3949-54.

84

Das A, Tan WL, Teo J, Smith DR. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neurooncol. 2002; 60: 117-25.

85

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015; 372: 2499-508.

86

Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, et al. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. J Neurooncol. 2019; 144: 205-10.

87

Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, et al. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012; 14: 1432-40.

88
Ostrom QT, Cote DJ. Epidemiology and Etiology of Glioblastoma. In: Otero JJ, Becker AP, editors. Precision Molecular Pathology of Glioblastoma. 1st ed. Cham: Springer; 2021. p. 3–19.
89

Hou L, Jiang J, Liu B, Han W, Wu Y, Zou X, et al. Smoking and adult glioma: a population-based case-control study in China. Neuro Oncol. 2016; 18: 105-13.

90

Ahn S, Han KD, Park YM, Bae JM, Kim SU, Jeun SS, et al. Cigarette smoking is associated with increased risk of malignant gliomas: a nationwide population-based cohort study. Cancers (Basel). 2020; 12: 1-10.

91

Ahn S, Han K, Lee JE, Jeun SS, Park YM, Joo W, et al. Association between height and the risk of primary brain malignancy in adults: a nationwide population-based cohort study. Neurooncology Adv. 2021; 3: vdab098.

92

Brenner AV, Sugiyama H, Preston DL, Sakata R, French B, Sadakane A, et al. Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958-2009. Eur J Epidemiol. 2020; 35: 591-600.

93

Jiang B, Liu H, Sun D, Sun H, Ru X, Fu J, et al. Mortality due to primary brain tumours in China and detection rate in people with suspected symptoms: a nationally representative cross-sectional survey. World J Surg Oncol. 2021; 19: 1-12.

94

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96.

95

Ma X, Lv Y, Liu J, Wang D, Huang Q, Wang X, et al. Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China. J Clin Neurosci. 2009; 16: 1595-8.

96

Zhang X, Bailey SD, Lupien M. Laying a solid foundation for Manhattan--‘setting the functional basis for the post-GWAS era’. Trends Genet. 2014; 30: 140-9.

97

Gallagher MD, Chen-Plotkin AS. The post-GWAS era: from association to function. Am J Hum Genet. 2018; 102: 717-30.

98

Umans BD, Battle A, Gilad Y. Where are the disease-associated eQTLs? Trends Genet. 2021; 37: 109-24.

99

Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018; 19: 581-90.

100

Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum Mol Genet. 2019; 28: R133-42.

101

Zhao Y, Chen G, Yu H, Hu L, Bian Y, Yun D, et al. Development of risk prediction models for glioma based on genome-wide association study findings and comprehensive evaluation of predictive performances. Oncotarget. 2018; 9: 8311-25.

102

Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun. 2019; 10: 3328.

103

Ramroop JR, Gerber MM, Toland AE. Germline variants impact somatic events during tumorigenesis. Trends Genet. 2019; 35: 515-26.

104

Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, et al. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov. 2017; 7: 410-23.

105

Sun X, Xue A, Qi T, Chen D, Shi D, Wu Y, et al. Tumor mutational burden is polygenic and genetically associated with complex traits and diseases. Cancer Res. 2021; 81: 1230-9.

106

Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014; 24: 1765-73.

107

Zhang Y, Ma W, Fan W, Ren C, Xu J, Zeng F, et al. Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma. Cell Death Dis. 2021; 12: 1140.

108

Oldrini B, Vaquero-Siguero N, Mu Q, Kroon P, Zhang Y, Galán-Ganga M, et al. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nat Commun. 2020; 11: 3883.

109

Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015; 28: 318-28.

110

Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015; 25: 316-27.

111

Xu PF, Li C, Xi SY, Chen FR, Wang J, Zhang ZQ, et al. Whole exome sequencing reveals the genetic heterogeneity and evolutionary history of primary gliomas and matched recurrences. Comput Struct Biotechnol J. 2022; 20: 2235-46.

112

Körber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, et al. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell. 2019; 35: 692-704.e12.

113

Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021; 39: 509-28.e20.

114

Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020; 580: 517-23.

115

van de Geer WS, Hoogstrate Y, Draaisma K, Robe PA, Bins S, Mathijssen RHJ, et al. Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. Neurooncology Adv. 2022; 4: vdab177.

116

Stasik S, Juratli TA, Petzold A, Richter S, Zolal A, Schackert G, et al. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma. Neoplasia. 2020; 22: 800-8.

117

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, Aldape KD, Alfred Yung WK, Salama SR, Cooper LAD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015; 372: 2481-98.

118

Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019; 576: 112-20.

119

Nørøxe DS, Yde CW, Østrup O, Michaelsen SR, Schmidt AY, Kinalis S, et al. Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study. Mol Oncol. 2020; 14: 2727-43.

120

Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, et al. Prospective clinical sequencing of adult glioma. Mol Cancer Ther. 2019; 18: 991-1000.

121

Zhang L, Jia W, Ji N, Li D, Xiao D, Shan GL, et al. Construction of the National Brain Tumor Registry of China for better management and more efficient use of data: a protocol. BMJ Open. 2021; 11: e040055.

Cancer Biology & Medicine
Pages 1440-1459
Cite this article:
Mo Z, Xin J, Chai R, et al. Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. Cancer Biology & Medicine, 2022, 19(10): 1440-1459. https://doi.org/10.20892/j.issn.2095-3941.2022.0418

153

Views

2

Downloads

6

Crossref

6

Web of Science

6

Scopus

Altmetrics

Received: 16 July 2022
Accepted: 20 September 2022
Published: 03 November 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return